Psych Vivas · Psychopharmacology — pharmacogenomics
Pharmacogenomics in psychiatry — consultant viva
Fellowship viva on psychiatric PGx actionability, HLA safety, CYP dosing, trial literacy, and commercial panel pitfalls.
On this page & tools
Target exams
FRANZCPMRCPsychABPNMD-DNB
Prompt
Examiner cards: PK vs PD genes; PM/IM/NM/UM; CPIC SSRIs 2015 vs 2023; HLA-B*15:02; HLA-A*31:01; Chen Taiwan; phenoconversion; atomoxetine CYP2D6; GUIDED; PRIME Care; SLC6A4 ban; AGNP TDM.
Station structure
Time: 8–10 minutes. Depth: consultant teaching registrar. Expect named guidelines (CPIC), HLA alleles, phenotype language, and one nuanced trial point each for GUIDED and PRIME Care.[1][3][6]
Continue reading
Psychiatry Fellowship Pro
You have read the opening of this viva. The complete unit — every section and its primary-source references — is part of the Psychiatry Fellowship fellowship atlas.
References10Show ledgerHide ledger
- [1]Bousman CA, Stevenson JM, Ramsey LB, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants Clin Pharmacol Ther, 2023.PMID 37032427
- [2]Hicks JK, Bishop JR, Sangkuhl K, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors Clin Pharmacol Ther, 2015.PMID 25974703
- [3]Phillips EJ, Sukasem C, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update Clin Pharmacol Ther, 2018.PMID 29392710
- [4]Chen P, Lin JJ, Lu CS, et al. Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan N Engl J Med, 2011.PMID 21428768
- [5]McCormack M, Alfirevic A, Bourgeois S, et al. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans N Engl J Med, 2011.PMID 21428769
- [6]Oslin DW, Lynch KG, Shih MC, et al. Effect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder: The PRIME Care Randomized Clinical Trial JAMA, 2022.PMID 35819423
- [7]Greden JF, Parikh SV, Rothschild AJ, et al. Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: A large, patient- and rater-blinded, randomized, controlled study J Psychiatr Res, 2019.PMID 30677646
- [8]Brown JT, Bishop JR, Sangkuhl K, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for Cytochrome P450 (CYP)2D6 Genotype and Atomoxetine Therapy Clin Pharmacol Ther, 2019.PMID 30801677
- [9]Hiemke C, Bergemann N, Clement HW, et al. Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017 Pharmacopsychiatry, 2018.PMID 29390205
- [10]Bousman CA, Bengesser SA, Aitchison KJ, et al. Review and Consensus on Pharmacogenomic Testing in Psychiatry Pharmacopsychiatry, 2021.PMID 33147643